
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 11, 2012

LIFEVANTAGE CORPORATION

(Exact name of registrant as specified in its charter)

Colorado
(State or other Jurisdiction
of Incorporation)

001-35647
(Commission
File Number)

90-0224471
(IRS Employer
Identification No.)

9815 S. Monroe Street, Suite 100, Sandy, UT
(Address of Principal Executive Offices)

84070
(Zip Code)

Registrant's telephone number, including area code: (801) 432-9000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 Regulation FD Disclosure.

LifeVantage Corporation's (the "Company") President and Chief Executive Officer, Douglas C. Robinson, and its Chief Financial Officer, David Colbert, will be presenting at the Wedbush 2012 California Dreamin' Conference "The New York Edition," to be held on December 11th and 12th in New York City, New York. A copy of the written presentation materials to be used at the conference is furnished as an exhibit to this report.

The information in this Item 7.01, including the information contained in the copy of the presentation materials to be used at the conference, is being furnished, not filed, pursuant to Regulation FD. Accordingly, such information will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of such information is not intended to, and does not, constitute a determination or admission by the Company as to the materiality of such information. Such information contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that represent the Company's current expectations and beliefs. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. For a detailed discussion of these risks and uncertainties, please read the risk factors set forth in the Company's periodic reports (including its reports on Form 10-K and 10-Q) filed by the Company with the Securities and Exchange Commission. The forward-looking statements set forth the Company's beliefs as of the date that such information was first provided, and the Company assumes no duty to update the forward-looking statements to reflect any change except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Copy of written presentation materials to be used by the Company at Wedbush conference

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: December 11, 2012

LifeVantage Corporation

By: /s/ Rob Cutler

Rob Cutler

General Counsel



Wedbush
13th Annual Consumer Conference
December 11, 2012

Presented By
Douglas C. Robinson, President and CEO

Safe Harbor Statement

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "look forward to," "anticipates" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in such statements. These forward-looking statements are based on our current expectations and beliefs concerning future events affecting us and involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are discussed in greater detail in the our Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption "Risk Factors", and in other documents filed by us from time to time with the Securities and Exchange Commission. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to us as of today, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Health Claims Disclaimer

Statements made in this presentation have not been evaluated by the Food and Drug Administration. LifeVantage products are not intended to treat, cure, prevent or mitigate any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors.

Company Profile

- NASDAQ 2012: LFDV
- Headquarters: SLC, UT
- Q1 2013 Rev: \$52.9 M
- Q1 2013 Op Income: \$6.9 M
- Cash Balance: \$25.2 M
- Debt: \$0
- Fiscal Year End June 30
- Launched network marketing model 2009



A leader in healthy living with scientifically validated, research-backed solutions to fight oxidative stress

Investment Summary


Nasdaq: LRVN	
Headquarters: Salt Lake City, UT	
Fiscal Year End June 30	
Recent Price (12/07/12)	\$2.00
52-Week Range	\$1.28 - \$3.98
Shares Outstanding	113 M
Fully Diluted Shares	134 M
Average Daily Volume (3 months)	393,000
Market Capitalization (12/07/12)	\$236 M
Sales Multiple ⁽¹⁾⁽²⁾	1.8
Price / Earnings ⁽¹⁾⁽²⁾	18.2
FY12 Revenue ⁽¹⁾	\$126.2 M
FY12 Operating Income ⁽¹⁾	\$21.5 M
FY12 Cash Flow from Operations ⁽¹⁾	\$19.4 M

(1) Based on Fiscal Year End June 30, 2012

(2) Current market capitalization / fiscal year end June 30, 2012 revenue

(3) Current stock price / fiscal year end June 30, 2012 EPS

LifeVantage Evolution



Strategically Positioned in Growth Markets

Consumer confidence in supplements is on the rise (1)

Positioned in multiple large industry categories projected to grow


Global Nutraceutical Product Market

Projected to Grow 6.3% Annually
Through 2017 (2)



Nutrition/Healthy Living Industry

2011 U.S. Sales \$117 B (4)



Cosmeceuticals (3)

U.S. Retail Sales



(1) nutraceuticalsworld.com, May 17, 2012

(2) Transparency Market Research. Nutraceuticals Product Market: Global Size, Segment and Country Analysis & Forecasts (2007-2017), March 2012

(3) Packaged Facts, Cosmeceuticals in the U.S., April 2012

(4) NBJ 2011 Direct Selling Report

Benefits of Network Marketing

Typical Retail Customer Experience



- Lack of education
- Overwhelmed by multiple choices
- Limited customer service

LifeVantage Customer Experience



- Authentic "person-to-person" approach
- Addresses real issues
- Education-based message

Today...A Two Product Lineup

Protandim®

- The Nrf2 Synergizer®
- Backed by patents, considerable research and peer-reviewed studies



©2012 LifeVantage


TrueScience Anti-Aging Cream

- Scientifically-based skin cream
- Designed to reduce the signs of aging



Revenue and Product Distribution

Worldwide Distribution
Q1 2013 Revenue



- The Americas
- Asia/Pacific




Advanced nutraceutical dietary supplement, Protandim®, the Nrf2 Synergizer®



LifeVantage TrueScience® Anti-Aging Skin Cream

Product Category
Q1 2013 Revenue



- Protandim
- TrueScience

Protandim® - the Nrf2 Synergizer®


- Unique, patented blend of naturally-occurring plant compounds
- Scientifically validated
- Shown to reduce oxidative stress up to 40% in 30 days
- Nrf2 activation
 - Shown to combat oxidative stress by increasing body's own production of powerful, natural antioxidant enzymes at the genetic level



Oxidative Stress refers to the cellular and tissue damage caused by chemically reactive oxygen radicals and related oxidants. It is a result of the metabolic process and may promote some of the undesirable effects of aging.

Synergistic Proven Formula

Synergistic induction of heme oxygenase by the components of Protandim in human brain-derived cells ⁽¹⁾



- All five ingredients ⁽²⁾ together (Protandim formula) produced 18-fold increase in expression of antioxidant gene
- Protected by six patents
 - Four composition of matter patents - granted in 2007, 2008, and 2011
 - One methods and use patent granted in 2009
 - Australia patent in 2012

(1) Free Radical Biology & Medicine study. Represents alcohol extract from 30 ug Protandim or components per ml medium
(2) Ashwagandha, Bacopa Extract, Green Tea Leaf Extract, Milk Thistle Extract, Turmeric Extract.

Scientific Evidence and Validation

- Peer-reviewed studies:

Journal	Institution	Publication Date
Free Radical Biology & Medicine	University of Colorado	8/28/2005
Free Radical Biology & Medicine	University of Colorado	11/17/2008
PlosOne	Louisiana State	4/22/2009
Circulation, a journal of the American Heart Association	Virginia Commonwealth University	11/2/2009
Journal of Dietary Supplements	University of Colorado	6/1/2010
PlosOne	Louisiana State University	7/30/2010
Free Radical Biology & Medicine	The Ohio State University	03/15/2011
Enzyme Research	Louisiana State University	03/23/2011
Molecular Aspects Medicine	University of Colorado	10/15/2011
American Journal of Physiology	University of Colorado	4/1/2012
Oxidative Medicine Cellular Longevity	Colorado State University	5/22/2012
Free Radical Biology & Medicine	Colorado State University	11/29/2012

And others at www.pubmed.gov

- Additional studies are underway to test Protandim's efficacy with respect to the fight against oxidative stress primarily through Nrf2 activation.

TrueScience Anti-Aging Cream



- Optimal protection for healthful, vibrant and youthful skin
 - Addresses the visible effects of stress and aging of skin
 - Produces a result you can see

- Formulated and developed with scientists and dermatologists
 - Protects skin from a variety of factors that contribute to aging and the symptoms of unhealthy skin
 - Contains ingredients from Protandim found to prevent cell damage internally
 - Contains six skin-rebuilding essentials and 11 active anti-aging ingredients most effective in improving skin tone, texture and appearance.



Additional Product Focus

New product additions by internal development and/or external acquisition

- Must fit in the "Healthy Living" category
- Seeking scientifically validated, clinically proven products
- Internal R&D focused on the reduction of oxidative stress primarily through Nrf2 activation
 - Supplements for companion pets
- Healthy living trends target (for example)
 - Physical fitness
 - Wellness routines
 - Anti-aging
 - Weight management
 - Nutrition



Geographic Diversity

Opportunity for further international expansion



(1) Full distribution planned starting on Jan. 1, 2013

Active Customer Mix

By definition, our Active Independent Distributors and Active Preferred Customers have purchased product(s) during the prior three months.



Approximately 8 out of 10 new enrollments are Preferred Customers

Continuous Training and Education

- Annual Convention
- Quarterly Elite Academies
- Monthly Premier Schools
- Weekly Leadership Calls
- Super Saturday Events
- Concentrate on enabling middle ranks
- Replicated websites
- Business tools



During fiscal 2012, LifeVantage Corporation and distributors held over 13,000 training and opportunity meetings across the network.

Manufacturing & Quality Focus

- On December 5th, the Company initiated a voluntary recall of select lots of Protandim.
- We are committed to producing safe, scientifically validated products.
- “Reputational Capital” is an operational imperative and is earned with business transparency and high ethical standards.
- Based on what we know today, potential gross cost impact is \$7M ⁽¹⁾.
 - ~\$3.5 M for material disposition and replacement.
 - ~\$2.5 M for shipping replacement product.
 - ~\$1.0 M for other voluntary recall related expenses.

Manufacturing & Quality Focus


“The likelihood that any one tablet of Protandim® will contain a small piece of wire is extremely low. Even if ingested the likelihood that the small pieces of wire would result in any adverse health event is also extremely low.”

David W K Acheson MD, FRCP (Leavitt Partners)

Dr. Acheson is an internal medicine physician and was former Associate Commissioner for Foods at the FDA and Chief Medical Officer at the FDA Center for Food Safety and Applied Nutrition.


- What have we done?
 - Hired an independent GMP expert to evaluate our processes and provide process recommendations
 - Enhanced manufacturing processes with multiple redundancies, some of which now exceed industry standards
- The redundant processes include:
 - Additional filtering process at the raw material stage, beyond what is performed at the raw material supplier
 - Magnet at the powder stage prior to tableting
 - Metal detector post tableting
 - Metal detector post bottling

Revenue Growth



Income & Cash Generation

Launched Network Marketing in 2009



Strengthening Balance Sheet

	Sept. 30, 2012	June 30, 2012	June 30, 2011
Cash	\$25.2 M	\$24.6 M	\$6.4 M
Current Assets	\$41.7 M	\$38.8 M	\$10.3 M
Derivative Liabilities	\$0	\$0*	\$27.3 M
Long-Term Debt	\$0	\$0	\$0
Shareholder Equity (Deficit)	\$34.1 M	\$28.3 M	(\$20.8 M)

**Eliminated all derivative liabilities as of 3/31/12*


Improved balance sheet and increased transparency of financial statements were key FY 2012 successes.

FY 2013 Outlook

Guidance ⁽¹⁾

- Revenue: \$250 - \$260 M
- Operating Income: \$34.5 - \$38.2 M
- Operating Margin: 13.8% - 14.7%
- Fully Diluted EPS \$0.18 - \$0.20
- Diluted Shares Outstanding 129 M

Annual Revenue Growth



(1) Based on FY13 guidance issued on 9/10/2012

Positioned for Long-Term Profitable Growth

- Increasing Geographic Diversity
- Improved Financial Health
- Experienced and Successful Management Team
- Complementary Products in Pipeline
- Expanding Distributor Network & Customer Base
- Growing Scientific Support & Awareness of Protandim

Nasdaq: LFTN	
Headquarters: Salt Lake City, UT	
Fiscal Year End June 30	
Recent Price (12/07/12)	\$2.00
52-Week Range	\$1.28 - \$3.98
Shares Outstanding	113 M
Fully Diluted Shares	134 M
Avg. Daily Volume (3-mo)	393,000
Market Capitalization (12/07/12)	\$236 M
Sales Multiple ⁽¹⁾⁽²⁾	1.8
Price / Earnings ⁽¹⁾⁽³⁾	18.2
FY12 Revenue ⁽¹⁾	\$126.2 M
FY12 Operating Income ⁽¹⁾	\$21.5 M
FY12 Cash Flow from Operations ⁽¹⁾	\$19.4 M

(1) Based on Fiscal Year End June 30, 2012

(2) Current market capitalization / fiscal year end June 30, 2012 revenue

(3) Current stock price / fiscal year end June 30, 2012 EPS

©LifeVantage 2012

Contact Information

LifeVantage

9815 South Monroe Street
Salt Lake City, UT 84070
801.432.9000

LifeVantage.com

ICR

12400 Wilshire Boulevard, Suite 1200
Los Angeles, CA 90025
310.954.1100

icrinc.com